Skip to main content
  • Some Second-Line T2D Options Linked With CV Risk

    Observational study reported higher risk with sulfonylureas and basal insulin

    Two commonly used diabetes drugs -- basal insulin and sulfonylureas -- were associated with significantly increased cardiovascular risk when given as second-line therapy for patients with type 2 diabetes (T2D), according to a large observational study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details